- Home
- FPF vs RIGL Comparison
FPF vs RIGL Comparison
Compare FPF & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FPF | RIGL |
|---|---|---|
| Founded | 2013 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 884.9M |
| IPO Year | 2013 | 2000 |
Fundamental Metrics
Financial Performance| Metric | FPF | RIGL |
|---|---|---|
| Price | $16.21 | $48.17 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $45.67 |
| AVG Volume (30 Days) | ★ 177.6K | 175.2K |
| Earning Date | 01-01-0001 | 05-05-2026 |
| Dividend Yield | ★ 8.08% | N/A |
| EPS Growth | N/A | ★ 1867.68 |
| EPS | N/A | ★ 1.32 |
| Revenue | N/A | ★ $294,282,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $12.75 |
| P/E Ratio | ★ N/A | $36.28 |
| Revenue Growth | N/A | ★ 64.15 |
| 52 Week Low | $16.10 | $24.84 |
| 52 Week High | $19.50 | $52.24 |
Technical Indicators
Market Signals| Indicator | FPF | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 16.80 | 60.61 |
| Support Level | N/A | $43.78 |
| Resistance Level | $18.18 | $49.50 |
| Average True Range (ATR) | 0.25 | 1.48 |
| MACD | -0.08 | -0.05 |
| Stochastic Oscillator | 6.14 | 87.21 |
Price Performance
Historical ComparisonAbout FPF First Trust Intermediate Duration Preferred & Income Fund of Beneficial Interest
First Trust Inter Dur Pref& Income Fund is a diversified, closed-end management investment company. Its primary investment objective is to seek a high level of current income. Further, it has a secondary objective of capital appreciation. The Fund invests in the traditional preferred securities, hybrid preferred securities, floating rate & fixed-to-floating rate preferred securities, debt securities, convertible securities, and contingent convertible securities issued by U.S. and non-U.S. companies. Its investment portfolio includes industries such as Banks, Insurance, Capital Markets, Electric Utilities, Oil, Gas & Consumable Fuels, Food Products, and others.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.